OAB Drug May Improve Outcomes in Botulinum Toxin Recipients
Pharmacologic therapy may improve symptoms in patients with refractory overactive bladder who receive intravesical onabotulinum toxin-A injections.
All articles by Natasha Persaud
Factors Contributing to Darbepoetin Responsiveness in CKD
In a Japanese study, approximately 1 in 8 CKD patients with anemia failed to respond to darbepoetin alfa therapy.
Eplerenone May Improve Albumin Excretion in T2D With Acceptable Safety
Research suggests the use of additional treatment options, such as the mineralocorticoid receptor antagonist eplerenone, might prevent or delay overt diabetic nephropathy.
Vadadustat Noninferior to Darbepoetin in CKD
Despite favorable efficacy data, the HIF-PHI failed to demonstrate noninferiority to the ESA in patients with CKD with respect to the primary MACE safety endpoint.
Dapagliflozin Reduces Hyperkalemia Risk in Heart Failure Treated With MRAs
Secondary results from the DAPA-HF trial suggest the sodium-glucose cotransporter 2 inhibitor may enable use of mineralocorticoid receptor antagonists in some patients with heart failure.
Empagliflozin Beneficial in Heart Failure With Reduced Ejection Fraction
In a trial, empagliflozin reduced the risks for heart failure hospitalization and renal outcomes in patients with heart failure with reduced ejection fraction.
Ferric Citrate May Improve Iron Parameters Better Than Ferrous Sulfate in CKD
Transferrin saturation and ferritin concentrations improved significantly more in the ferric citrate than ferrous sulfate group over 12 weeks.
Finerenone Found to Delay Progression of Diabetic Kidney Disease
Early results from the phase 3 FIDELIO-DKD study also show that finerenone reduces the risk for a cardiovascular secondary endpoint in patients with diabetic kidney disease.
Tolvaptan Lowers Kidney Stone Risk in ADPKD
Tolvaptan improves the urinary lithogenic risk profile of patients with autosomal dominant polycystic kidney disease, according to researchers.
Limited ESA Use in COVID-19 Patients Recommended
Anemia in patients hospitalized with COVID-19 can be severe, but in most cases, clinicians should limit their use of erythropoiesis-stimulating agents.
